Treat Rev, 2020, 82: 101946.

[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet,
2018, 391(10127): 1301-1314.
[3] 马中山, 马云玲, 冯丽. 放疗在原发性肝癌非手术治疗中的地
位与作用[J]. 中华放射医学与防护杂志, 2010, 30(1): 102-104.
[Ma ZH, Ma YL, Feng L. The role of radiotherapy in non-surgical
treatment of primary liver cancer[J]. Zhonghua Fang She Yi Xue
Yu Fang Hu Za Zhi, 2010, 30(1): 102-104.]
[4] Park S, Yoon WS, Rim CH. Indications of external radiotherapy
for hepatocellular carcinoma from updated clinical guidelines:
Diverse global viewpoints[J]. World J Gastroenterol, 2020, 26(4):
393-403.
[5] Choi SH, Seong J. Strategic application of radiotherapy for
hepatocellular carcinoma[J]. Clin Mol Hepatol, 2018, 24(2):
114-134.
[6] Kimura SH, Ikawa M, Ito A, et al. Cyclin G1 is involved in G2/M
arrest in response to DNA damage and in growth control after
damage recovery[J]. Oncogene, 2001, 20(25): 3290-3300.
[7] 许刚, 王燕, 吴立广, 等. Cyclin G1对肝癌细胞HepG2放射敏感
度的影响及其机制[J]. 肿瘤防治研究, 2017, 44(9): 590-595. [Xu
G, Wang Y, Wu LG, et al. Effect of cyclin G1 on radiosensitivity
of hepatocellular carcinoma HepG2 cells and its mechanism[J].
Zhoong Liu Fang Zhi Yan Jiu, 2017, 44(9): 590-595.]
[8] Choi C, Koom WS, Kim TH, et al. A prospective phase 2
multicenter study for the efficacy of radiation therapy following
incomplete transarterial chemoembolization in unresectable
hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2014,
90(5): 1051-1060.
[9] Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation
therapy combined with transcatheter arterial chemoembolization
for small hepatocellular carcinoma[J]. J Gastroenterol Hepatol,
2013, 28(3): 530-536.
[10] Wahl DR, Stenmark MH, Tao Y, et al. Outcomes After
Stereotactic Body Radiotherapy or Radiofrequency Ablation for
Hepatocellular Carcinoma[J]. J Clin Oncol, 2016, 34(5): 452-459.
[11] Wei X, Jiang Y, Zhang X, et al. Neoadjuvant Three-Dimensional
Conformal Radiotherapy for Resectable Hepatocellular Carcinoma
With Portal Vein Tumor Thrombus: A Randomized, Open-Label,
Multicenter Controlled Study[J]. J Clin Oncol, 2019, 37(24):
2141-2151.
[12] Liu PH, Hsu CY, Hsia CY, et al. Prognosis of hepatocellular
carcinoma: Assessment of eleven staging systems[J]. J Hepatol,
2016, 64(3): 601-608.
[13] Wang CY, Li S. Clinical characteristics and prognosis of 2887
patients with hepatocellular carcinoma: A single center 14 years
experience from China[J]. Medicine (Baltimore), 2019, 98(4):
e14070.
[14] 田小强, 鲁世慧, 王礼学, 等. 不可手术的原发性肝癌放疗
效果影响因素及预后分析[J]. 东南大学学报(医学版), 2019,
38(6): 1029-1034. [Tian XQ, Lu SH, Wang LX, et al. Analysis of
efficiency and influence factor of intensity-modulated radiotherapy
for inoperable primary hepatocellular carcinoma[J]. Dongnan Da
Xue Xue Bao(Yi Xue Ban), 2019, 38(6): 1029-1034.]
[15] 田璐, 吴炯, 朱捷, 等. C5L2表达与肝癌患者预后分析[J]. 复旦学报
(医学版), 2017, 44(3): 280-287. [Tian L, Wu J, Zhu J, et al. Prognostic
analysis of C5L2 in patients with hepatocellular carcinoma[J]. Fu
Dan Xue Bao(Yi Xue Ban), 2017, 44(3): 280-287.]
[16] Deng Y, Zhou X, Xiang X, et al. NOR1 expr‍ession and its
relationship with prognosis in patients with hepatocellular
carcinoma[J]. J BUON, 2017, 22(5): 1186-1190.
[17] Zhao X, Chen Y, Mao Q, et al. Overexpr‍ession of YTHDF1 is
associated with poor prognosis in patients with hepatocellular
carcinoma[J]. Cancer Biomark, 2018, 21(4): 859-868.
[18] Chawla SP, Bruckner H, Morse MA, et al. A Phase Ⅰ-Ⅱ
Study Using Rexin-G Tumor-Targeted Retrovector Encoding a
Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic
Cancer[J]. Mol Ther Oncolytics, 2018, 12: 56-67.
[19] Yan J, Jiang JY, Meng XN, et al. MiR-23b targets cyclin G1 and
suppresses ovarian cancer tumorigenesis and progression[J]. J Exp
Clin Cancer Res, 2016, 35: 31.
[20] Wen W, Ding J, Sun W, et al. Cyclin G1-mediated epithelialmesenchymal
transition via phosphoinositide 3-kinase/Akt
signaling facilitates liver cancer progression[J]. Hepatology, 2012,
55(6): 1787-1798.
[21] Xu L, Lin X, Zheng Y, et al. Silencing of heat shock protein 27
increases the radiosensitivity of non?small cell lung carcinoma
cells[J]. Mol Med Rep, 2019, 20(1): 613-621.